Helix Biopharma Corp., of Richmond Hill, Ontario, closed a private placement of C$1.311 million (US$1.059 million). Each unit sold at C$1.20 consists of one common share and one warrant to purchase an additional share at C$1.50 within five years of issuance. Helix plans to use the proceeds for working capital and research and development activities.
Jazz Pharmaceuticals plc, of Dublin, said the initial purchasers of its private offering of $500 million aggregate principal amount of 1.5 percent exchangeable senior notes due 2024 by Jazz Investments I Ltd., its wholly owned subsidiary, have exercised in full their option to purchase an additional $75 million aggregate principal amount of notes. Jazz used the net proceeds from the initial offering, together with cash on hand, to repay $500 million of outstanding borrowings under its revolving credit facility on Aug. 28. Proceeds from the additional notes’ sale will be used for general corporate purposes, including potential business development activities.